255 related articles for article (PubMed ID: 12952836)
1. Matrix metalloproteinases as novel disease markers in Takayasu arteritis.
Matsuyama A; Sakai N; Ishigami M; Hiraoka H; Kashine S; Hirata A; Nakamura T; Yamashita S; Matsuzawa Y
Circulation; 2003 Sep; 108(12):1469-73. PubMed ID: 12952836
[TBL] [Abstract][Full Text] [Related]
2. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
4. [Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis].
Fiedorczyk M; Klimiuk PA; Sierakowski S; Domysławska I; Chwiećko J
Przegl Lek; 2005; 62(12):1321-4. PubMed ID: 16786739
[TBL] [Abstract][Full Text] [Related]
5. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.
Huang CY; Wu TC; Lin WT; Leu HB; Lin CP; Lin SJ; Chen JW
Eur J Clin Invest; 2006 Feb; 36(2):76-84. PubMed ID: 16436088
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
[TBL] [Abstract][Full Text] [Related]
7. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.
Masuhara K; Nakai T; Yamaguchi K; Yamasaki S; Sasaguri Y
Arthritis Rheum; 2002 Oct; 46(10):2625-31. PubMed ID: 12384920
[TBL] [Abstract][Full Text] [Related]
8. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
9. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.
Kuropkat C; Plehn S; Herz U; Dünne AA; Renz H; Werner JA
Anticancer Res; 2002; 22(4):2221-7. PubMed ID: 12174907
[TBL] [Abstract][Full Text] [Related]
10. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
[TBL] [Abstract][Full Text] [Related]
12. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
13. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis.
Rautelin HI; Oksanen AM; Veijola LI; Sipponen PI; Tervahartiala TI; Sorsa TA; Lauhio A
Ann Med; 2009; 41(3):208-15. PubMed ID: 18979291
[TBL] [Abstract][Full Text] [Related]
14. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
15. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis.
Fainardi E; Castellazzi M; Tamborino C; Trentini A; Manfrinato MC; Baldi E; Tola MR; Dallocchio F; Granieri E; Bellini T
Mult Scler; 2009 May; 15(5):547-54. PubMed ID: 19318509
[TBL] [Abstract][Full Text] [Related]
16. Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study.
Peake NJ; Khawaja K; Myers A; Jones D; Cawston TE; Rowan AD; Foster HE
Rheumatology (Oxford); 2005 Nov; 44(11):1383-9. PubMed ID: 16049050
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood levels of matrix metalloproteinases in patients referred for percutaneous balloon mitral valve commissurotomy.
Garr RJ; Krasuski RA; Eckart RE; Wang A; Pierce C; Kisslo KB; Harrison JK; Bashore TM
J Heart Valve Dis; 2006 May; 15(3):369-74. PubMed ID: 16784074
[TBL] [Abstract][Full Text] [Related]
19. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia.
El Messal M; Beaudeux JL; Drissi A; Giral P; Chater R; Bruckert E; Adlouni A; Chapman MJ
Clin Chim Acta; 2006 Apr; 366(1-2):185-9. PubMed ID: 16280123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
